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Radiotherapy (XRT) is often utilized in the curative management of many difficult to treat 
cancers, such as lung, head and neck, breast and esophageal cancers.[1, 2] Over the past 
several decades, advances in radiation delivery have significantly reduced the side effects of 
XRT.[3] Despite this improvement, long-term cardiovascular side effects, such as myocardial 
infarction, atherosclerosis, and stroke, remains one of the most common causes of late 
morbidity and mortality of cancer treatment.[1, 2, 4] In one clinical study, investigators found 
that patients who received XRT for breast cancer are up to 4 times more likely to suffer 
cardiovascular events 10 to 15 years after completing their cancer treatment.[3, 5] Despite 
radiation-induced blood vessel damage was first reported about a century ago, the 
underlying mechanism remains unclear.[5] Recent studies have revealed that the late-
cardiovascular events triggered by XRT may involve acute up-regulation of pro-
inflammatory cytokines and adhesion molecules at the endothelium of injured blood 
vessel.[6] While it is widely believed that the damage of endothelium occurs shortly after 
XRT treatment[2], there has been no direct observation of such injury. Furthermore, the lack 
of understanding of this injury process prevents the development of effective therapies for 
the damage.
One of the characteristics of endothelium damage is the exposure of collagen IV-rich 
basement membrane (BM) to the circulation system.[7] A number of studies attempted to use 
oligo(hydroxyproline)-based collagen mimetic peptide and collagen-binding recombinant 
protein to target the vascular basement membrane,[8] but all these targeting ligands failed to 
target the collagen IV fiber that makes up of 50 % of the basement membrane. A recent 
study found that a synthetic peptide with an amino acid sequence of KLWVLPK binds 
specifically to collagen IV fiber,[9] which provides unique opportunities to develop new 
collagen IV-targeting molecular probe to identify early-stage blood vessel damage induced 
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by XRT. In addition, such molecular targets afford potential novel targeted drug delivery 
system for preventive treatments. Biodegradable collagen IV-targeting peptide-conjugated 
PEGylated nanoparticles (NPs), such as poly(ethylene glycol)-poly(lactic-co-glycolic acid) 
(PEG-PLGA)-based di-block copolymer nanoparticles of 100 – 150 nm in diameter, are 
ideal for vascular basement membrane-targeting applications.[10] The active targeting PEG 
motif increases the circulation half-life of the NPs and allows the NPs to bind specifically to 
the basement membrane at the injured vessels.[10, 11] The use of biodegradable polymer can 
prevent the targeting NPs from irreversibly accumulating at the injury site and causing 
potential long-term damage.[12] In addition, techniques have been developed to encapsulate 
radioactive isotope and drug to di-block copolymer NPs for deep tissue imaging and 
preventative treatment.[13]
In this communication, we reported the first direct observation of an early-stage blood 
vessels injury induced by high-dose XRT via fluorescent-label BM-targeting NPs. To 
achieve our goal, we engineered biodegradable fluorescent-labeled collagen IV-targeting 
peptide-conjugated PEG-PLGA NPs. The physicochemical properties and in vitro toxicity of 
the BM-targeting NPs were fully investigated. Collagen IV fiber-based solid-phase binding 
assay and quantitative ex vivo imaging study in athymic nude (Nu) mice skin were used to 
elevate the binding affinity of the BM-targeting NPs to collagen IV fiber in the basement 
membrane. The ability of the BM-targeting NPs to identify an early-stage blood vessel 
injury induced by high-dose XRT was verified in a murine model via standard full-body in 
vivo fluorescence imaging technique.
Fluorescent rhodamine B (Rhod)-labeled BM-targeting PEG-PLGA NPs were prepared via 
nanoprecipitation method[14] using a mixture of PEG(2K)-PLGA(15K) and collagen IV-
targeting peptide-conjugated PEG(5K)-PLGA(10K) di-block copolymers as building blocks 
of the NPs in the presence of Rhod-labeled PLGA(30K) (Figure 1a and Experimental). 
During the nanoprecipitation process, the high-molecular weight hydrophobic Rhod-labeled 
PLGA was encapsulated within the hydrophobic PLGA core of the NPs.[15] The cysteine (C) 
end at the GGGC linker of the collagen IV-targeting peptide (amino acid sequence: 
KLWVLPKGGGC) was conjugated to maleimide-functionalized PEG(5K)-PLGA(10K) via 
metal-free thiol-maleimide ‘click’ reaction[16] prior to the preparation of PEG-PLGA NPs, 
and the structure of the peptide functionalized di-block copolymer was confirmed by 1H 
NMR spectroscopy (Figure S1). Non-targeting PEG-PLGA NPs have been prepared for 
control studies used methoxyl-functionalized PEG(5K)-PLGA(10K) instead of collagen IV-
targeting peptide-conjugated PEG(5K)-PLGA(55K) as a building block of the NPs. Figure 
1b shows the transmission electron microscopy (TEM) images of the BM-targeting NPs and 
non-targeting NPs. The number-average diameter (Dn) of the BM-targeting and non-
targeting PEG-PLGA NPs were found to be 83 and 81 nm, respectively, as determined by 
TEM. This is consistent with the mean hydrodynamic diameter (Dh) of about 135 nm 
(polydispersity index, PDI ≈ 0.14, Figure S2) and mean Dn of about 110 nm (Figure 1c) 
determined by dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) 
techniques on NP aqueous dispersions, where the long hydrophilic PEG chains were fully 
hydrated in aqueous environment. Based on the NTA result, it was calculated that 1 mg/mL 
of the BM-targeting NPs and non-targeting NPs contain approximately 9.0 ± 0.2 × 1011 NPs 
(i.e. 1.5 nM, Figure 1c). Aqueous electrophoresis measurements confirmed that the 
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conjugated cationic lysine (K)-containing collagen IV-targeting peptide is located on the 
surface of the BM-targeting NPs with a less anionic mean zeta potential (ζ) of −21.6 mV 
recorded for the BM-targeting NPs (dispersed in 1 mM NaCl electrolyte) versus a more 
anionic mean ζ of −28.3 mV recorded for the non-targeting NPs (Figure 1d), despite both 
NPs having near-zero mean zeta potentials when dispersed in 0.1 M phosphate buffered 
saline (PBS) due to compression of electrical double-layer in the high ionic strength 
physiological buffer. Both PEG-PLGA NPs have negative zeta potentials at pH 7 (in 1 mM 
NaCl electrolyte) because of the deprotonated carboxylic acid end-group in the hydrophobic 
PLGA block (pKa ≈ 4).[17] Spectroscopic measurements confirmed the presence of Rhod-
labeled PLGA in both nanoparticles with a characteristic Rhod B visible absorption band 
centered at 560 nm and a narrow emission band centered at 580 nm (Figure 1e). Further in 
vitro fluorescence imaging study indicated the average photon fluxes recorded at an 
emission wavelength of 600 nm were linearly increased with the concentration of Rhod-
labeled BM-targeting NPs upon excitation at 570 nm (Figure 1f). An in vitro toxicity study 
indicated that relatively high concentrations (up to 15 nM) of the BM-targeting NPs and 
non-targeting NPs showed very low cytotoxicities against KB epithelial cells (Figure S3).
A quantitative in vitro study was performed to elevate the binding affinity of the BM-
targeting NPs to collagen IV fibers. We briefly incubated 0 – 1.5 nM (0 – 1 mg/mL) of BM-
targeting NPs and non-targeting NPs in a collagen IV-coated well plate, and washed with 
PBS and fetal bovine serum (FBS) prior to spectroscopic measurements to quantify the 
amount of NPs binding to collagen IV fibers. As shown in Figure 2a and Figure S4, the 
fluorescence intensities (at 590 nm) of collagen IV-coated wells increased with the 
concentration of BM-targeting NPs, suggesting that the BM-targeting NPs dose-dependently 
bind to collagen IV fibers. Plateau binding can be observed when the concentration of BM-
targeting NPs reached about 0.74 nM. By fitting the dose-dependent fluorescence intensities 
to the Hill equation,[18] the Hill constant (nHill) and dissociation constant (Kd) were 
calculated to be 1.25 and 0.13 nM, respectively. This confirms that the BM-targeting NPs 
bind strongly and cooperatively to collagen IV. On the other hand, increasing the 
concentrations of non-targeting NPs only slightly increased the fluorescence intensities of 
collagen IV fibers, and the plateau fluorescent intensity is at least 10 times lower than that 
recorded for BM-targeting NPs. Quantitative data analysis indicated that the binding of the 
non-targeting NPs is non-cooperative (nHill < 1, the binding of one NP to a collagen fiber 
lower binding affinity for another NP[18]), and the dissociation constant of the non-targeting 
NPs is more than 10 times higher than that of BM-targeting NPs.
Next, we performed an ex vivo imaging study on freshly excised Nu mouse skin to 
investigate the binding affinity of BM-targeting NPs to collagen IV fibers in the basement 
membrane. Basement membrane was exposed to the bulk environments from the peritoneal 
surface prior to the ex vivo study. Figure 2b shows wide-field fluorescence images recorded 
for the ex vivo skin samples after incubated with different concentrations of BM-targeting 
NPs or non-targeting NPs. As shown in the Figure 2b(i–v), increasing the concentration of 
BM-targeting NPs progressively increased the fluorescence intensities at the basement 
membrane and allowed the identification of individual collagen fibers. Quantitative image 
analysis (Figure 2c) indicated the observed contrast effect is contributed by the binding of 
fluorescent BM-targeting NPs. Conversely, increasing the concentration of non-targeting 
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NPs did not significantly increase the fluorescence intensities at the basement membrane 
(Figures 2b(vi–ix) and d). This is due to the anti-biofouling character of the high molecular 
weight PEG, which prevents non-specific binding to the basement membrane.[19] The 
fluorescence intensity of this basement membrane after incubation with 150 pM of BM-
targeting NPs is about 10 times higher those incubated with non-targeting NPs. To further 
verify that the BM-targeting NPs bonded specifically to the basement membrane, we 
superficially sketched the letters “U N C” on the peritoneal surface of a piece of freshly 
excised mouse skin via a scalpel to expose the basement membrane before incubation with 
150 pM of BM-targeting NPs. As shown in Figure 2d, “U N C” is clearly visible and 
strongly fluorescent, indicating specific binding of the BM-targeting NPs to the collagen IV 
fibers in the basement membrane that were artificially exposed before the study. Both ex 
vivo imaging studies confirmed that the BM-targeting NPs bonded specifically to collagen 
IV-rich basement membrane.
Finally, we performed in vivo fluorescence imaging study with the aim of intravenous (i.v.) 
administrated BM-targeting NPs to investigate early-stage blood vessel injury induced by 
high-dose radiotherapy in healthy Nu mice. 10 days before the imaging study, the left flank 
of healthy Nu mice were subjected to a single high-dose XRT (30 Gy). Full-body 
fluorescence images (Figure 3a and Figure S5) were recorded pre-injection and 24 after tail-
vein i.v. injection of BM-targeting NPs or non-targeting NPs. As shown in Figures 3a(ii) and 
S5(a), the total photon flux recorded at the left flank in six out of seven Nu mice 
administrated with BM-targeting NPs were approximately 3.5 times higher than that 
recorded at the right flank (p < 0.005, Figure 3a(iii)), which indicates the accumulation of 
fluorescent BM-targeting NPs at the left flank. On the other hand, the total photon flux 
recorded at the left flank of irradiated mice administrated with non-targeting NPs was nearly 
identical to that recorded at the right flank (p = 0.22, Figures 3a(ii) and (iii)), and the total 
photon flux recorded at the right flank of mice administrated with BM-targeting NPs and 
non-targeting NPs was also nearly identical (p = 0.66, Figure 3a(ii), (iii) and S5). The 
quantitative in vivo imaging study confirmed that high-dose XRT damaged the endothelium 
of major blood vessels at the irradiated site, and exposed the basement membrane and 
nearby tissues to the circulation system, which allowed for the binding of circulating BM-
targeting NPs. Further histological study was performed to investigate the contrast effect 
observed at the left flank of irritated mice after the administration of the BM-targeting NPs. 
Figure 3b shows representative optical and fluorescence images of leg histological sections 
collected after the in vivo imaging study. Significant vascular injuries can be observed at the 
tunica intima (include endothelium, basement membrane) and tunica media of the left leg 
histological sections that were subjected to high-dose XRT (Figure 3b), whereas the right leg 
blood vessels remained relatively normal. However, only the histological sections collected 
from Nu mice administrated with BM-targeting NPs showed strong fluorescence intensities 
at the injured blood arteries and nearby tissues, suggesting that the increased photon flux 
recorded at the left flank of Nu mice administrated with BM-targeting NP is due to the 
binding of BM-targeting NPs to the injured blood vessels and nearby tissues.
In summary, we successfully engineered new fluorescent-labeled collagen IV-targeting 
peptide-conjugated BM-targeting PEG-PLGA NPs for the first direct observation of an 
early-stage vascular injury-induced by high-dose XRT. Quantitative in vitro study in 
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collagen IV-based solid-phase binding assay and quantitative ex vivo imaging studies in Nu 
mice skin demonstrated that BM-targeting NPs bind strongly and specifically to collagen IV 
fibers in the basement membrane. Intravenous administration of fluorescent BM-targeting 
NPs allowed us to observe an early-stage blood vessels injury-induced by high-dose XRT in 
a murine model via standard full body in vivo fluorescence imaging technique due to 
specific binding of BM-targeting NPs to the basement membrane of damaged blood vessels 
and surrounding tissues, which was confirmed by further histological study. The successful 
identification of an early-stage high-dose XRT-induced blood vessel injury should facilitates 
the developments of new preventative treatments for high-dose XRT-induced vascular 
diseases. In addition, the successful fabrication of BM-targeting PEG-PLGA NPs should 
facilitate the development of a new basement membrane-targeting drug delivery system to 
treat basement membrane-related complications, such as surgical adhesion, that have posed a 
major challenge in medicine for many years.
Experimental Section
Materials and Experimental Setup are provided in the Supporting Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) Scheme summarized the preparation of BM-targeting PEG-PLGA NPs and non-targeting 
PEG-PLGA NPs via nanoprecipitation method. The collagen IV-targeting peptide (Col(IV)-
TP) was conjugated to maleimide-functionalized PEG(5K)-PLGA(10K) prior to the prior to 
the preparation of BM-targeting NPs. (b) TEM images recorded for (i) BM-targeting and (ii) 
non-targeting NPs. (c) Number-average particle distribution curves recorded for 5 μg/mL of 
(i) BM-targeting NP and (ii) non-targeting NP dispersions, as determined by NTA method. It 
was determined that both NP dispersions contain about 4.5 × 109 particles per mL(d) Mean 
zeta potentials (ζ) of BM-targeting and non-targeting NPs dispersed in 1 mM NaCl 
electrolyte and 0.1 M PBS. (e) UV-visible absorption and fluorescence spectra recorded for 
Au et al. Page 9













BM-targeting NPs and non-targeting NPs. (f) In vitro fluorescence image recorded for (i) 
0.150, (ii) 0.375, (iii) 0.750, (iv) 1.125, and (v) 1.500 nM of BM-targeting NPs. (N.B. * 
denotes p < 0.05, i.e. statistical significance.)
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(a) Concentration-dependent fluorescence intensities recorded for collagen IV-coated well 
plate after incubated with different concentrations of BM-targeting NPs and non-targeting 
NPs. The inset table summarized the binding affinities of two different NPs after fitted to 
Hill equation. (b) Florescence images recorded for basement membrane-exposed disease-
free Nu mouse skin after incubation with (i) PBS and different concentrations of (ii–v) BM-
targeting NPs and (vi–ix) non-targeting NPs. The insert cartoon shows the wide-field 
fluorescence imaging method. (c) Concentration-dependent fluorescence intensities at 
basement membrane of artificially damaged Nu mouse skin after incubation with different 
concentrations of BM-targeting NPs and non-targeting NPs. (d) Wide-field fluorescent 
images of an artificially-damaged Nu mouse skin with “U N C” letters. (N.B. * denotes p < 
0.05, i.e. statistical significance. Fluorescence images were recorded using 200 ms exposure 
time.)
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(a) Representative in vivo optical and fluorescence overlaid images of high-dose X-ray 
irradiated healthy Nu mice recorded (i) pre-injection and (ii) 24 h after tail-vein i.v. injection 
of BM-targeting NPs (BM-NPs) or non-targeting NPs (NT-NPs). (See Figure S5 for the 
overlaid images of the remaining 6 Nu mice recorded 24 h after administration of BM-
targeting NPs and non-targeting NPs.) 6 out of 7 of the X-ray irradiated mice showed 
increased photon flux (shown in yellow-red) at left flank (irradiated site) after the 
administration of the BM-targeting NPs. (iii) The total photon fluxes at the left and right 
flanks of the irradiated mice recorded 24 h after i.v. administration of BM-targeting NPs or 
non-targeting NPs, as quantified from the corresponding in vivo fluorescence images. The 
inset cartoon and digital image show the setup for site-specific XRT. (b) Representative low- 
and high-magnification optical and fluorescent histological images of (i) left and (ii) right 
leg histological sections that collected after the in vivo imaging study. The blue arrows 
labeled the vascular injury region. Fluorescence basement membrane can be easily identified 
from the high magnification fluorescence image of left leg section collected from mouse 
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administrated with BM-targeting NPs. (N.B. n.s. denotes statistical insignificant; * denotes p 
< 0.05, i.e. statistical significance. L denotes lumen; TI denotes tunica intima which 
compose of endothelium (ED) and basement membrane (BM); TM denotes tunica media. 
Low magnification fluorescence images were recorded using 200 ms exposure time, high 
magnification images were recorded using 100 ms exposure time.)
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